Each dog with a POT1 mutation tended to have more than one enriched variant, with a similar observation in TRAF3. Therefore, the novel target drugs against POT1 and TRAF3 might have therapeutic potential for treating DLBCL in dogs. Here, TRAF3 is linked to diffuse large B-cell lymphoma.